ストックスクリーナーアプリを入手
0.54
6.15%
0.0313
アフターアワーズ：
.54
前日終値:
$0.5087
開ける：
$0.5145
24時間の取引高:
1.47M
Relative Volume:
0.30
時価総額：
$85.67M
収益：
$3,000
当期純損益:
$-140.95M
株価収益率:
-0.2641
EPS:
-2.0449
ネットキャッシュフロー:
$-90.89M
1週間 パフォーマンス:
+16.10%
1か月 パフォーマンス:
+16.00%
6か月 パフォーマンス:
-59.40%
1年 パフォーマンス:
-53.04%
1日の値動き範囲:
$0.4947
$0.54
1週間の範囲:
$0.4481
$0.54
52週間の値動き範囲:
$0.3772
$3.03
Fractyl Health Inc Stock (GUTS) Company Profile
Compare GUTS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
0.54 | 80.70M | 3,000 | -140.95M | -90.89M | -2.0449 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-15 | 開始されました | H.C. Wainwright | Buy |
| 2025-08-28 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-02-28 | 開始されました | Evercore ISI | Outperform |
| 2024-02-27 | 開始されました | BofA Securities | Buy |
| 2024-02-27 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Fractyl Health Inc (GUTS) 最新ニュース
Fractyl Health (GUTS) stock jumps 21% after hours: Here's what you should know - MSN
Buy Signal: Is Fractyl Health Inc undervalued by DCF analysisDip Buying & Low Volatility Stock Recommendations - baoquankhu1.vn
GUTS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GUTS Stock Price, Quote & Chart | FRACTYL HEALTH INC (NASDAQ:GUTS) - ChartMill
Fractyl Health Q4 2025 Earnings Call Transcript - MarketBeat
Portfolio Shifts: Is Fractyl Health Inc undervalued by DCF analysis2026 Volatility Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Fractyl Health, Inc. (GUTS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
If You Invested $1,000 in Fractyl Health (GUTS) - Stock Titan
Pharma News: Is Fractyl Health Inc benefiting from interest rate changes2026 Big Picture & Growth Oriented Trading Recommendations - baoquankhu1.vn
Fractyl Health (GUTS) Projected to Post Quarterly Earnings on Monday - MarketBeat
Fractyl Health Earnings Call: Revita Nears Key Pivotal Test - The Globe and Mail
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
HC Wainwright Forecasts Fractyl Health Q1 Earnings - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Merck & Company (MRK) and Abbott Laboratories (ABT) - The Globe and Mail
Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Market Recap: Is Fractyl Health Inc in a long term uptrend2026 Volume & Low Risk High Reward Ideas - baoquankhu1.vn
Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Decreases By 55.7% - MarketBeat
Fractyl Health (NASDAQ:GUTS) Earns Buy Rating from Canaccord Genuity Group - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN) - The Globe and Mail
Fractyl Health FY2029 EPS Forecast Lifted by HC Wainwright - MarketBeat
Fractyl Health Faces Significant Compliance Risks Under Global Anti-Corruption and Sanctions Laws - TipRanks
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating - Moomoo
Fractyl Highlights Revita Progress and 2025 Financial Results - The Globe and Mail
Fractyl Health, Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
Fractyl Health (GUTS) Stock Jumps 21% After Hours: Here's What You Should Know - Benzinga
Fractyl Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - ca.investing.com
Fractyl Health outlines 2026 De Novo submission plans with pivotal Revita data expected in early Q4 - MSN
Disease-Modifying Therapies for Obesity and Type 2 Diabetes: Revita and Rejuva Pipeline Overview - Minichart
Fractyl Health Inc’s 2025 Q4 Call: CPT Code Timing, Regulatory Readiness, and Ablation Targets Don’t Align - Bitget
GUTS: Pivotal study enrollment complete; Revita advances toward key 2026 data and de novo submission - TradingView
Fractyl Health Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Fractyl Health Q4 2025 sees cost cut, stock dips - Investing.com
Fractyl Health (NASDAQ:GUTS) Posts Narrower-Than-Expected Loss Ahead of Pivotal Trial Readout - ChartMill
FRACTYL HEALTH ($GUTS) Releases Q4 2025 Earnings - Quiver Quantitative
Fractyl Health (NASDAQ:GUTS) Releases Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times
Fractyl Health 2025 10-K: $0M Revenue, Net Loss $140.954M - TradingView
Fractyl Health (NASDAQ: GUTS) outlines Revita device and Rejuva gene therapy plans - Stock Titan
Fractyl Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Fractyl Health (Nasdaq: GUTS) widens 2025 loss but advances pivotal Revita - Stock Titan
Fractyl Health, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Fractyl Health, Inc. (GUTS) loses 77.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Fractyl Health (NASDAQ:GUTS) - intelligentinvestor.com.au
H.C. Wainwright Maintains a Buy Rating on Fractyl Health, Inc. (GUTS) with an $8 Price Target - Insider Monkey
Fractyl Health, Inc. (GUTS) moves to buy: Rationale behind the upgrade - MSN
Fractyl Health Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Fractyl Health (Nasdaq: GUTS) faces Nasdaq minimum bid-price warning - Stock Titan
Fractyl Health Inc (GUTS) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):